Crystal-Associated Arthritis: Calcium Pyrophosphate Arthritis

Pascual, Eliseo; Andrés, Mariano

doi:10.1007/978-3-030-99612-3_11

Cited by 1 publication

(2 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While bright field microscopy will allow the identification of CPP crystals’ characteristic morphology appearing as rhombuses, thin bars and parallelepipeds, compensated PLM additionally defines birefringence. 35 CPP crystals can often require meticulous scrutiny of the synovial fluid for correct detection as they often show no birefringence, can be found phagocytized, and can frequently be found inside vacuoles. 35 It often requires allocating additional time for careful examination of the sample to yield a diagnosis, as crystals can be sparsely distributed.…”

Section: Diagnosismentioning

confidence: 99%

“… 35 CPP crystals can often require meticulous scrutiny of the synovial fluid for correct detection as they often show no birefringence, can be found phagocytized, and can frequently be found inside vacuoles. 35 It often requires allocating additional time for careful examination of the sample to yield a diagnosis, as crystals can be sparsely distributed. Correct identification of CPP crystals in the synovial fluid of a suspected case is a major facilitator in reaching the correct diagnosis.…”

Section: Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis and Treatment of Calcium Pyrophosphate Deposition (CPPD) Disease: A Review

Cowley¹,

McCarthy²

2023

OARRR

View full text Add to dashboard Cite

Calcium Pyrophosphate Dihydrate (CPPD) crystal-related arthropathies are a common cause of acute and chronic arthritis caused by the deposition of calcium pyrophosphate crystals in joints and soft tissues, resulting in inflammation and joint damage. They present with a wide spectrum of clinical manifestations and often present challenges to diagnosis and management as they commonly affect older co-morbid patients. The challenges are compounded by a lack of a well-defined description of CPPD. However, an international expert-driven process is underway to develop CPPD classification criteria. Treatment is also problematic as unlike gout, there are no agents available that decrease the crystal burden. Treatment options have often been extrapolated from gout treatment pathways without having extensive trials or a solid evidence base. It is hoped the new CPPD classification guidelines will contribute to large multicentre studies, with well-defined patient cohorts, which will facilitate the production of high-quality evidence to guide the management of this condition. Here, we discuss the barriers and facilitators in diagnosing and treating CPPD-related arthropathy.

show abstract

Section: Diagnosismentioning

confidence: 99%

Section: Diagnosismentioning

confidence: 99%